Biorestorative Therapies, Inc. (NASDAQ:BRTX) Short Interest Update

Biorestorative Therapies, Inc. (NASDAQ:BRTX) saw a significant drop in short interest in the month of May. As of May 15th, there was short interest totaling 368,665 shares, a drop of 42.8% from the April 30th total of 644,870 shares. Based on an average daily trading volume, of 1,050,694 shares, the short-interest ratio is currently 0.4 days. Approximately 1.7% of the shares of the stock are short sold.

Hedge Funds Weigh In On Biorestorative Therapies

Several institutional investors and hedge funds have recently made changes to their positions in the business. Virtu Financial LLC raised its position in Biorestorative Therapies by 102.4% in the 3rd quarter. Virtu Financial LLC now owns 24,351 shares of the company’s stock worth $35,000 after purchasing an additional 12,319 shares during the period. Citadel Advisors LLC bought a new position in shares of Biorestorative Therapies during the third quarter valued at about $152,000. Finally, DRW Securities LLC purchased a new position in shares of Biorestorative Therapies in the fourth quarter worth about $55,000. Institutional investors own 69.38% of the company’s stock.

Biorestorative Therapies Price Performance

BRTX stock traded down $0.01 during mid-day trading on Wednesday, hitting $0.35. 850,234 shares of the stock were exchanged, compared to its average volume of 11,582,546. The business has a fifty day moving average price of $0.26 and a 200 day moving average price of $0.66. Biorestorative Therapies has a 12 month low of $0.16 and a 12 month high of $2.05. The stock has a market capitalization of $8.89 million, a price-to-earnings ratio of -0.33 and a beta of 0.67.

Biorestorative Therapies (NASDAQ:BRTX) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.01. Biorestorative Therapies had a negative return on equity of 508.42% and a negative net margin of 3,088.27%.The company had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.31 million. As a group, equities analysts forecast that Biorestorative Therapies will post -0.66 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Biorestorative Therapies in a report on Wednesday, May 27th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Sell”.

About Biorestorative Therapies

Biorestorative Therapies Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.

Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy.